Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Short Interest Update

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) was the target of a large decrease in short interest in February. As of February 28th, there was short interest totalling 14,600 shares, a decrease of 67.3% from the February 13th total of 44,700 shares. Based on an average trading volume of 59,100 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Fresenius SE & Co. KGaA in a research report on Monday, February 3rd.

Fresenius SE & Co. KGaA Trading Up 3.7 %

OTCMKTS FSNUY traded up $0.39 during trading hours on Monday, hitting $11.02. 45,104 shares of the company were exchanged, compared to its average volume of 56,628. Fresenius SE & Co. KGaA has a 52 week low of $6.57 and a 52 week high of $11.16. The company has a quick ratio of 1.05, a current ratio of 1.36 and a debt-to-equity ratio of 0.57. The stock has a 50-day moving average price of $9.79 and a 200 day moving average price of $9.34. The stock has a market cap of $24.62 billion, a PE ratio of 52.48 and a beta of 1.02.

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.18 earnings per share for the quarter. The company had revenue of $6.01 billion for the quarter. Analysts forecast that Fresenius SE & Co. KGaA will post 0.79 earnings per share for the current fiscal year.

Remove Ads

Fresenius SE & Co. KGaA Company Profile

Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.